A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, multicenter, randomized controlled, phase 3 study to explore the efficacy and safety of neoadjuvant tislelizumab plus lenvatinib in patients with resectable HCC at high risk of recurrence.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Dobry stan ogólny (zdolność do wykonywania codziennych czynności)
- •Potwierdzony rak wątroby możliwy do usunięcia chirurgicznie
- •Dobra funkcja wątroby (klasa A)
- •Oczekiwana długość przeżycia co najmniej 6 miesięcy
- •Prawidłowe wyniki badań krwi (liczba krwinek, działanie nerek)
- •Prawidłowe zdolności krzepnięcia krwi
- •Kobiety w wieku rozrodczym muszą stosować antykoncepcję
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Trial contact
Tianqiang Song
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.